Search results
Results from the WOW.Com Content Network
CSL Behring's parent company, CSL Limited, is headquartered in Melbourne, Victoria, Australia. [3] Previously known as ZLB Behring, the company's history dates back to 1904 when Behringwerke was founded in Germany by Emil von Behring, winner of the first Nobel Prize in Medicine as the inventor of serum therapy or serology. [4]
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines , antivenom , and cell culture reagents used in various medical and genetic research and ...
The remaining assets of Armour Pharmaceuticals are now part of CSL Behring. [10] Armour's Factor VIII product "Factorate" was widely reported as infecting thousands of hemophiliacs worldwide with HIV during the 1980s; [11] [12] there have also been allegations that the firm suppressed evidence showing the product was defective. [13]
In 1996, ZLB Bioplasma (part of CSL Behring) was given approval to sell Rhophylac in Europe. Effectiveness was demonstrated in a clinical trial in 2003 and in 2004 Rhophylac was approved in the United States. [25]
CSL Plasma is a subsidiary of its sister company CSL Behring, itself a subsidiary of CSL Limited, a biotechnology company based in Melbourne, Australia. [2] [ P 2] It is headquartered in Boca Raton, Florida, [1] and operates a total of 320 collection centers in the United States, [P 3] and a further 19 more in other nations including China, Hungary, and Germany as of 2023.
In 1996, Armour and Behringwerke merged, and became Centeon. In 1999, Centeon changed its name to Aventis Behring after the parent companies, Rorer and Hoechst AG merged to become Aventis. In 2004, CSL completed its acquisition of Aventis Behring for $925m, today known as CSL Behring. [37]
Garadacimab, sold under the brand name Andembry is a human monoclonal antibody used for the treatment of hereditary angioedema. [1] Garadacimab is a monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.
CSL Behring Canada. 2019. 221855. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H, et al. (Beriplex P/N Anticoagulation Reversal Study Group) (April 2008). "Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial". Journal of Thrombosis and Haemostasis.